# US 2018/0369303 A1 · Oncolytic rhabdovirus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0369303 A1
- Document ID: US20180369303A1
- Status: Published application
- Kind: A1
- Application number: 16/101,265
- Filed: 2018-08-10
- Published: 2018-12-27
- Earliest claimed: 2010-10-21
- Assignees: Turnstone Limited Partnership
- Applicants: Turnstone Limited Partnership
- Inventors: David F. STOJDL; John BELL
- Web page: https://patentgrep.com/patent/US20180369303A1

## CPC

- A61K 35/766: Rhabdovirus, e.g. vesicular stomatitis virus
- A61K 35/768: Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 35/761: Adenovirus
- A61K 35/763: Herpes virus
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12N 2760/20032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2760/20045: Special targeting system for viral vectors
- C12N 2760/20221: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2760/20222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/20232: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2760/20271: Demonstrated in vivo effect
- C12N 2810/6081: rhabdoviridae, e.g. VSV
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Embodiments of the invention include compositions and methods related to non-VSV rhabdoviruses and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.

## Claims

### Claim 1

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an oncolytic recombinant rhabdovirus encoding a G protein from a first rhabdovirus and M, P, N and L proteins from a second rhabdovirus.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the G protein has at least about 85% amino acid sequence identity to an Isfahan virus G protein, a Chandipura virus G protein, a Maraba virus G protein, a Bahia Grande virus G protein, a Klamath virus G protein, or a Farmington virus G protein.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, wherein the oncolytic recombinant rhabdovirus encodes a G protein having at least about 85% amino acid sequence identity to an Isfahan virus G protein, a Chandipura virus G protein, a Maraba virus G protein, or a Muir Springs virus G protein.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, wherein the oncolytic recombinant rhabdovirus encodes a G protein having at least about 85% amino acid sequence identity to an Isfahan virus G protein, a Maraba virus G protein, or a Muir Springs virus G protein.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein the oncolytic recombinant rhabdovirus encodes a G protein having at least about 85% amino acid sequence identity to a Maraba virus G protein.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the oncolytic recombinant rhabdovirus encodes M, P, N and L proteins from vesicular stomatitis virus (VSV).

### Claim 7 (depends on 2)

The pharmaceutical composition of claim 2, wherein the oncolytic recombinant rhabdovirus encodes M, P, N and L proteins from vesicular stomatitis virus (VSV).

### Claim 8 (depends on 3)

The pharmaceutical composition of claim 3, wherein the oncolytic recombinant rhabdovirus encodes M, P, N and L proteins from vesicular stomatitis virus (VSV).

### Claim 9 (depends on 4)

The pharmaceutical composition of claim 4, wherein the oncolytic recombinant rhabdovirus encodes M, P, N, and L proteins from vesicular stomatitis virus (VSV).

### Claim 10 (depends on 5)

The pharmaceutical composition of claim 5, wherein the oncolytic recombinant rhabdovirus encodes M, P, N, and L proteins from vesicular stomatitis virus (VSV).

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, wherein said composition comprises 103 to 1013 plaque forming units (pfu) of the oncolytic recombinant rhabdovirus.

### Claim 12 (depends on 1)

A method for treating cancer in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 1.

### Claim 13 (depends on 12)

The method of claim 12, wherein the cancer is selected from the group consisting of lung cancer, head and neck cancer, breast cancer, cancer of the central nervous system, pancreatic cancer, prostate cancer, renal cancer, bone cancer, testicular cancer, cervical cancer, ovarian cancer, gastrointestinal cancer, lymphoma, liver cancer, colon cancer, melanoma, and bladder cancer.

### Claim 14 (depends on 12)

The method of claim 12, wherein the cancer is metastatic.

### Claim 15 (depends on 12)

The method of claim 12, wherein the subject is a human.

### Claim 16 (depends on 12)

The method of claim 12, wherein the composition is administered by intraperitoneal, intravascular, intramuscular, intratumoral, subcutaneous or intranasal administration.

### Claim 17 (depends on 16)

The method of claim 16, wherein the composition is administered by intratumoral or intravascular administration.

### Claim 18 (depends on 12)

The method of claim 12, wherein the composition is administered multiple times.

### Claim 19 (depends on 12)

The method of claim 12, further comprising administering an additional anti-cancer therapy selected from the group consisting of chemotherapy, radiotherapy, and immunotherapy.

### Claim 20

A method for treating cancer in a subject comprising administering to the subject an effective amount of an oncolytic recombinant rhabdovirus encoding a G protein from a first rhabdovirus and M, P, N and L proteins from a second rhabdovirus.

### Claim at position 21

21-24. (canceled)
